Table 1.
Cost data used in analysis
| Cost category | Cost used, £ (95% CI) | Source |
|---|---|---|
| Docetaxel acquisition, administration and monitoring costs (per course) WHO status 0 and age <60 yr WHO status 0 and age 60–64 yr WHO status 0 and age 65–69 yr WHO status 0 and age ≥70 yr WHO status 1–2 and age <60 yr WHO status 1–2 and age 60–64 yr WHO status 1–2 and age 65–69 yr WHO status 1–2 and age ≥70 yr |
1897 (1777–1999) 1947 (1844–2025) 1847 (1733–1945) 1610 (1468–1738) 1422 (1044–1772) 1524 (1236–1822) 1798 (1561–2007) 1663 (1413–1873) |
Analysis of STAMPEDE individual patient data (Supplementary material) |
| Adverse event costs (per event) Additional cost associated with neutropenia Additional cost associated with febrile neutropenia |
128 (NAa) 1363 (NAa) |
NHS reference costs [23] |
| Annual cost of monitoring Hormone-sensitive year 1 Hormone-sensitive years 2–5 Castrate-resistant On chemotherapy, abiraterone, or enzalutamide |
684 (NAb) 538 (NAb) 1764 (NAb) 2256 (NAb) |
Previous studies [31], NICE appraisals [32], expert opinion, NHS reference costs [23] |
| Annual costs of long-term management Constant c First year on SOC First year on SOC + Doc Age 60–64 yr Age 65–69 yr Age ≥70 yr WHO status 1 and 2 Nodal status N+ Nodal status NX (unknown) Health state: hormone-sensitive M1 bone Health state: hormone-sensitive M1 visceral Health state: CRPC M0 or M1 lymph node Health state: CRPC M1 bone Health state: CRPC M1 bone + SRE Health state: CRPC M1 visceral |
1209 (970–1453) 222 (107–342) 762 (524–995) −222 (−479 to 38) −177 (−429 to 74) 42 (−289 to 369) 390 (110–663) 279 (92–456) 474 (−337 to 1278) 876 (642–1123) 342 (51–661) 633 (448–799) 2295 (1978–2617) 3507 (2890–4075) 2397 (1723–3088) |
Analysis of STAMPEDE individual patient data (Supplementary material) |
| Annual life-extending therapy costs Health state: hormone-sensitive M0 or M1 lymph node Year 1 Year 2 Year 3 Health state: hormone-sensitive M1 bone Year 1 Year 2 Year 3 Health state: hormone-sensitive M1 visceral Year 1 Year 2 Year 3 Health state: CRPC M0 or M1 lymph node Year 1 Year 2 Year 3 Health state: CRPC M1 bone Year 1 Year 2 Year 3 Health state: CRPC M1 bone + SRE Year 1 Year 2 Year 3 Health state: CRPC M1 visceral Year 1 Year 2 Year 3 |
204 (7–615) 315 (7–856) 162 (55–286) 1278 (475–2141) 2469 (960–4234) 465 (213–1044) 9 (8–10) 9 (7–9) 96 (8–1567) 9831 (4894–16 010) 5226 (1020–9814) 3534 (1907–5708) 14 661 (10 914–18 671) 7488 (3875–11 599) 7344 (3758–8576) 12 861 (7774–18 112) 9120 (3888–14 899) 11 541 (5002–15 186) 7977 (1255–16 229) 24 534 (7–123,060) 3822 (7–9557) |
Analysis of STAMPEDE individual patient data |
| End of life (per prostate cancer-related death) | 6687 (535–20 257) | Round et al [33] |
CI = confidence interval; WHO = World Health Organisation; CRPC = castrate-resistant prostate cancer; SRE = skeletal-related event; NHS = National Health Service; NICE = National Institute for Health and Care Excellence.
a
Confidence interval not available as data represents a unit cost.
b
No confidence interval available as data obtained from expert opinion and NICE guidance.
c
The impact of each covariate is shown relative to a reference patient with M0 hormone-sensitive disease, not on the first year of treatment, aged <60 yr, with WHO status 0, and node-negative disease.